Reclassification of Membranoproliferative Glomerulonephritis: Identification of a New GN: C3GN

Overview

Journal World J Nephrol

Publisher Baishideng Publishing Group

Specialty Nephrology

Date 2016 Jul 27

PMID 27458560

Citations 8

Authors

Maurizio Salvadori

Giuseppina Rosso

Affiliations

Soon will be listed here.

Abstract

This review revises the reclassification of the membranoproliferative glomerulonephritis (MPGN) after the consensus conference that by 2015 reclassified all the glomerulonephritis basing on etiology and pathogenesis, instead of the histomorphological aspects. After reclassification, two types of MPGN are to date recognized: The immunocomplexes mediated MPGN and the complement mediated MPGN. The latter type is more extensively described in the review either because several of these entities are completely new or because the improved knowledge of the complement cascade allowed for new diagnostic and therapeutic approaches. Overall the complement mediated MPGN are related to acquired or genetic cause. The presence of circulating auto antibodies is the principal acquired cause. Genetic wide association studies and family studies allowed to recognize genetic mutations of different types as causes of the complement dysregulation. The complement cascade is a complex phenomenon and activating factors and regulating factors should be distinguished. Genetic mutations causing abnormalities either in activating or in regulating factors have been described. The diagnosis of the complement mediated MPGN requires a complete study of all these different complement factors. As a consequence, new therapeutic approaches are becoming available. Indeed, in addition to a nonspecific treatment and to the immunosuppression that has the aim to block the auto antibodies production, the specific inhibition of complement activation is relatively new and may act either blocking the C5 convertase or the C3 convertase. The drugs acting on C3 convertase are still in different phases of clinical development and might represent drugs for the future. Overall the authors consider that one of the principal problems in finding new types of drugs are both the rarity of the disease and the consequent poor interest in the marketing and the lack of large international cooperative studies.

Citing Articles

A compared histopathological study on kidneys and eye bulbs in distinct clinical presentations of canine leishmaniasis by Leishmania infantum.

Dos Santos R, Estrela-Lima A, Conrado-Dos-Santos W, Oria A, de Sousa Goncalves R, Silva D Vet Res Commun. 2024; 48(4):2243-2261.

PMID: 38717733 DOI: 10.1007/s11259-024-10379-z.

[Electron microscopy in nephropathology].

Porubsky S Pathologie (Heidelb). 2022; 44(2):84-94.

PMID: 36480038 DOI: 10.1007/s00292-022-01164-3.

Immunotactoid Glomerulopathy with Nontuberculous Mycobacterial Infection: A Novel Association.

Shimizu Y, Wakabayashi K, Iwasaki H, Kishida C, Seki S, Okuma T Case Rep Nephrol Dial. 2021; 11(2):136-146.

PMID: 34250031 PMC: 8255749. DOI: 10.1159/000515583.

PD-1 immunobiology in glomerulonephritis and renal cell carcinoma.

Curran C, Kopp J BMC Nephrol. 2021; 22(1):80.

PMID: 33676416 PMC: 7936245. DOI: 10.1186/s12882-021-02257-6.

Diverse Clinical Presentations of C3 Dominant Glomerulonephritis.

Hanna R, Hou J, Hasnain H, Arman F, Selamet U, Wilson J Front Med (Lausanne). 2020; 7:293.

PMID: 32695788 PMC: 7338606. DOI: 10.3389/fmed.2020.00293.

References

Fremeaux-Bacchi V, Legendre C . The emerging role of complement inhibitors in transplantation. Kidney Int. 2015; 88(5):967-73. DOI: 10.1038/ki.2015.253. View

Smith R, Harris C, Pickering M . Dense deposit disease. Mol Immunol. 2011; 48(14):1604-10. PMC: 3142282. DOI: 10.1016/j.molimm.2011.04.005. View

Tortajada A, Yebenes H, Abarrategui-Garrido C, Anter J, Garcia-Fernandez J, Martinez-Barricarte R . C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest. 2013; 123(6):2434-46. PMC: 3668852. DOI: 10.1172/JCI68280. View

Sethi S, Haas M, Markowitz G, DAgati V, Rennke H, Jennette J . Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol. 2015; 27(5):1278-87. PMC: 4849835. DOI: 10.1681/ASN.2015060612. View

Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M . Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015; 88(5):1153-60. DOI: 10.1038/ki.2015.227. View

Jokiranta T, Solomon A, Pangburn M, Zipfel P, Meri S . Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999; 163(8):4590-6. View

Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan B, Ozdemir B . Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol. 2014; 29(7):1283-7. DOI: 10.1007/s00467-013-2748-5. View

Skattum L, Martensson U, Sjoholm A . Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies. J Intern Med. 1998; 242(6):455-64. DOI: 10.1111/j.1365-2796.1997.tb00018.x. View

Daha M, Fearon D, Austen K . C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol. 1976; 116(1):1-7. View

10.

Barbour T, Pickering M, Cook H . Dense deposit disease and C3 glomerulopathy. Semin Nephrol. 2013; 33(6):493-507. PMC: 3820036. DOI: 10.1016/j.semnephrol.2013.08.002. View

11.

Sanchez-Moreno A, de la Cerda F, Cabrera R, Fijo J, Lopez-Trascasa M, Bedoya R . Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol. 2014; 29(10):2055-9. DOI: 10.1007/s00467-014-2839-y. View

12.

Licht C, Heinen S, Jozsi M, Loschmann I, Saunders R, Perkins S . Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 2006; 70(1):42-50. DOI: 10.1038/sj.ki.5000269. View

13.

Daina E, Noris M, Remuzzi G . Eculizumab in a patient with dense-deposit disease. N Engl J Med. 2012; 366(12):1161-3. DOI: 10.1056/NEJMc1112273. View

14.

Habib R, Gubler M, Loirat C, Maiz H, Levy M . Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int. 1975; 7(4):204-15. DOI: 10.1038/ki.1975.32. View

15.

Sethi S, Sukov W, Zhang Y, Fervenza F, Lager D, Miller D . Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010; 56(5):977-82. PMC: 3970198. DOI: 10.1053/j.ajkd.2010.06.021. View

16.

Zhang Y, Meyer N, Wang K, Nishimura C, Frees K, Jones M . Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol. 2012; 7(2):265-74. PMC: 3280037. DOI: 10.2215/CJN.07900811. View

17.

Sethi S, Fervenza F . Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012; 366(12):1119-31. DOI: 10.1056/NEJMra1108178. View

18.

McCaughan J, ORourke D, Courtney A . Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant. 2012; 12(4):1046-51. DOI: 10.1111/j.1600-6143.2011.03923.x. View

19.

Sethi S, Fervenza F, Smith R, Haas M . Overlap of ultrastructural findings in C3 glomerulonephritis and dense deposit disease. Kidney Int. 2015; 88(6):1449-1450. DOI: 10.1038/ki.2015.313. View

20.

le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M . Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis. 2014; 65(3):484-9. DOI: 10.1053/j.ajkd.2014.09.025. View